 |
20 Diseases |  |
6 Trials |
|
6 Trials |  |
1040 News |  |
| 12345678910111213...1516» |
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Prescriptive appropriateness of dalbavancin in acute bacterial skin and skin structure infections in adults: an integrated approach between clinical profile, patient- and health system-related factors and focus on environmental impact. (Pubmed Central) - Jan 16, 2025
No abstract available
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Retrospective data, Journal: Dalbavancin for the treatment of bone and joint infections: a meta-analysis. (Pubmed Central) - Jan 15, 2025
This meta-analysis showed that dalbavancin is as effective as SOC for the treatment of patients with OAI infections. More data are needed to validate these findings.
- || Nuvocid (oritavancin) / Melinta Therap, Menarini, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department. (Pubmed Central) - Dec 14, 2024
This review focuses on the role of long-acting LGPs in the ED setting for select patients presenting with ABSSSI, aiming to avoid hospitalizations, expedite patient discharge, and prevent readmissions while acknowledging potential limitations of therapy. Additionally, it provides insights into strategies and considerations specifically relevant to implementing this therapeutic approach in the ED.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Molecular insights into Dalbavancin's blockade of ACE2-spike protein interaction in SARS-CoV-2. (Pubmed Central) - Dec 11, 2024
The energy of Lys353 was also dominated by vdW interaction. These results and analysis may provide constructive insights and suggestions for the design and development of anti-SARS-CoV-2 drugs, thereby advancing the progress in viral treatment.
- | Nuvocid (oritavancin) / Melinta Therap, Menarini, Zeven (dalbavancin) / RaQualia, AbbVie
Journal: In-situ Formation and evaluation of N-Nitrosamine Drug Substance Related Impurities in Glycopeptides implying Orbitrap mass spectrometry. (Pubmed Central) - Nov 30, 2024
Using CPCA the potency scores and acceptable intakes for the NDSRIs were evaluated. Thus, this work aims to enhance the safety and efficacy of GPs ensuring compliance with the regulatory standards by advancing the understanding of NDSRIs in GPs.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections. (Pubmed Central) - Nov 27, 2024
Depending on individual MICs and protein binding, a dalbavancin regimen of 1500 mg every 3 to 5 weeks therefore appears to be a valuable option for outpatient therapy of VAD infections. Therapeutic drug monitoring should be considered to manage inter-individual variability and to support clinicians in long-term treatments of subacute and chronic infections.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Retrospective data, Journal: Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections. (Pubmed Central) - Nov 27, 2024
Dalbavancin proved to be effective for skin and skin structure infections, as well as for difficult-to-treat infections in highly comorbid patients. Regarding tolerability, our results support the use of dalbavancin for long-lasting treatments of deep-seated infections.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Chronic antibiotic suppressive therapy with dalbavancin: a case series. (Pubmed Central) - Nov 21, 2024
No adverse events were detected. Larger studies are needed to better clarify dalbavancin off-label uses and the most appropriate dose regimen.
- | Invanz (ertapenem) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
Journal: A Challenging Case of Isolated Pulmonic Valve Endocarditis With Septic Embolic and High-Grade Bacteremia. (Pubmed Central) - Nov 21, 2024
Isolated pulmonic valve endocarditis is a very rare entity. Prompt recognition of isolated pulmonic valve endocarditis and multidisciplinary management is key to improving outcomes among patients with this extremely rare condition.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization. (Pubmed Central) - Oct 21, 2024
Despite dalbavancin treatment with pharmacokinetic management, emerging dalbavancin resistance in S. epidermidis was observed, resulting in treatment failure. This outcome led to a prosthesis revision and long-term suppressive antibiotic therapy, with no recurrence of PJI after an 18?month follow-up.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing? (Pubmed Central) - Oct 6, 2024
This outcome led to a prosthesis revision and long-term suppressive antibiotic therapy, with no recurrence of PJI after an 18?month follow-up. The addition of heparin to a dalbavancin lock solution did not affect its bioactivity against staphylococcal biofilms irrespective of its preservation time under freezing.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. (Pubmed Central) - Sep 26, 2024
However, further studies comparing dalbavancin with standard of care are needed. CRD42023430032.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical data, Journal: One and Done? An Evaluation of the Clinical Outcomes of Single- and Multi-Dose Dalbavancin Use in the Pediatric Population. (Pubmed Central) - Sep 21, 2024
Following the utilization of DAL, high clinical success and low rates of adverse effects were observed with high patients' and parents' satisfaction. While larger, confirmatory real-world studies are needed, our findings support safe off-label DAL use in select pediatric patients.
- | Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus aureus Biofilms on Synthetic and Biological Vascular Grafts. (Pubmed Central) - Sep 15, 2024
While larger, confirmatory real-world studies are needed, our findings support safe off-label DAL use in select pediatric patients. In this in
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. (Pubmed Central) - Sep 12, 2024
It is used in both outpatient and inpatient settings due primarily to its convenience as a single-dose treatment regimen and to facilitate early hospital discharge. Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: a case series. (Pubmed Central) - Sep 12, 2024
Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile. Prescribing dalbavancin as first-line intravenous antibiotic for cellulitis prevents admission, saving bed-days and admission-related costs.
- Zeven (dalbavancin) / RaQualia, AbbVie
Dalbavancin Rationale and Clinical Outcomes in Patients Hospitalized with Serious Bacterial Infections at an Urban Safety Net Hospital: an Observational Cohort (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3080;
- Zeven (dalbavancin) / RaQualia, AbbVie
Admission Avoidance: A Protocol for Using Dalbavancin in the Emergency Department for Acute Bacterial Skin and Skin Structure Infections (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3071;
- Evaluation of Risk Factors for Short Inpatient Hospital Stays for the Treatment of Cellulitis (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3067;
- Zeven (dalbavancin) / RaQualia, AbbVie
Real-World Effectiveness of Dalbavancin for Invasive Gram-Positive Bacterial Infections (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2618;
- A Retrospective Review of Long-Acting Lipoglycopeptide Utilization at a VA Tertiary Teaching Medical Center (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2072;
- Percutaneous Mechanical Aspiration in Drug Use Associated-Infective Endocarditis (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1853;
- Zeven (dalbavancin) / RaQualia, AbbVie
Quantifying the Potential Impact of Dalbavancin on Health Care Metrics Associated with Outpatient Parenteral Antibiotic Therapy Management of Streptococcus and Staphylococcus Infections (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1515;
- Zeven (dalbavancin) / RaQualia, AbbVie
Dabbling with Dalbavancin: Implementation and Cost-savings of an Inpatient-to-Outpatient Dalbavancin Pathway (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1511;
- Zeven (dalbavancin) / RaQualia, AbbVie
Dalbavancin workflow for inpatient discharges: a multidisciplinary model (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1494;
- Real World Outpatient Utilization of Novel Anti-MRSA Antimicrobials: Patterns in Prescribing and Cost of Oral and Long-Acting Injectable Anti-MRSA Therapies in United States Medicaid Beneficiaries (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1118;
- Zeven (dalbavancin) / RaQualia, AbbVie
Dabbling with Dalbavancin: Implementation and Cost-savings of an Inpatient-to-Outpatient Dalbavancin Pathway (Halls JK - Arena 4) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_870;
- Zeven (dalbavancin) / RaQualia, AbbVie
Real-World Effectiveness of Dalbavancin for Invasive Gram-Positive Bacterial Infections (Halls JK - Arena 1) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_850;
- || Nuvocid (oritavancin) / Melinta Therap, Menarini, Zeven (dalbavancin) / RaQualia, AbbVie, Zevtera (ceftobiprole) / Basilea
Review, Journal: Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians. (Pubmed Central) - Sep 1, 2024
The use of TDM may play an important role for the optimal management of patients with MRSA infections and may impact on patient outcomes by increasing efficacy and reducing the risk of adverse events. TDM may be implemented in clinical practice, however several limitations such as the wide variability in the methodology and the need for skilled personnel need to be considered.
- || Zeven (dalbavancin) / RaQualia, AbbVie
PK/PD data, Journal: Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections. (Pubmed Central) - Aug 22, 2024
A decrease in C-RP is related to dalbavancin exposure in osteoarticular infections. Targeting dalbavancin plasma concentrations above the efficacy threshold may be associated with effective treatment.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal, Treatment costs: The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI. (Pubmed Central) - Aug 5, 2024
Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle? (Pubmed Central) - Aug 5, 2024
At the same time, this strategy allowed a more efficient allocation of hospital beds. Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal, HEOR: Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network. (Pubmed Central) - Aug 5, 2024
Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical. Assuming a 12-day hospitalization required for the treatment of ABSSSI or to complete the treatment of osteomyelitis or spondilodiscitis, the treatment with dalbavancin results in a cost reduction of more than
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal, Gram positive: Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview. (Pubmed Central) - Aug 5, 2024
Assuming a 12-day hospitalization required for the treatment of ABSSSI or to complete the treatment of osteomyelitis or spondilodiscitis, the treatment with dalbavancin results in a cost reduction of more than No abstract available
- Zeven (dalbavancin) / RaQualia, AbbVie
BILATERAL MRSA PNEUMONIA PRESENTING AS PULMONARY MASS-LIKE NODULARITIES IN A MIDDLE-AGED FEMALE WITH HISTORY OF BENIGN BREAST MASS (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1189;
Clinicians must be careful in the interpretation of clinical picture in patients who have shared risk factors of entirely different diagnoses. Imaging findings should be viewed in the context of additional confirmatory tests such as tissue biopsy or fluid culture.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Off-label use of dalbavancin in children: a case series. (Pubmed Central) - Jul 31, 2024
Imaging findings should be viewed in the context of additional confirmatory tests such as tissue biopsy or fluid culture. Dalbavancin was a safe, effective and convenient alternative in selected paediatric patients with complicated non-ABSSSI infections caused by Gram-positive bacteria.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal, HEOR: Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings. (Pubmed Central) - Jul 31, 2024
Dalbavancin was a safe, effective and convenient alternative in selected paediatric patients with complicated non-ABSSSI infections caused by Gram-positive bacteria. The new single-dose dalbavancin ED pathway for ABSSSI treatment, which was previously implemented at 11 U.S. EDs, offers robust cost savings compared to inpatient usual care.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. (Pubmed Central) - Jul 30, 2024
The new single-dose dalbavancin ED pathway for ABSSSI treatment, which was previously implemented at 11 U.S. EDs, offers robust cost savings compared to inpatient usual care. In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.
- | Nuvocid (oritavancin) / Melinta Therap, Menarini, Zeven (dalbavancin) / RaQualia, AbbVie
Observational data, Journal, Gram positive: What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study. (Pubmed Central) - Jul 27, 2024
Long half-life lipoglycopeptides contribute to changing the paradigm in the management of acute bacterial infections, as infectiologists now consider a range of indications and patient profiles for one single drug. Oritavancin strengthens the therapeutic arsenal in numerous infections from BJIs to urinary tract infections and could help to manage specific clinical situations, on top of providing potential benefits for the hospital's budget.
- Zeven (dalbavancin) / RaQualia, AbbVie
Dalbavancin as an option for treatment of S. aureus bacteremia (408 B) - Jul 15, 2024 - Abstract #IDWeek2024IDWEEK_544;
- Zeven (dalbavancin) / RaQualia, AbbVie
Emergency and outpatient implementation of Dalbavancin use (408 B) - Jul 15, 2024 - Abstract #IDWeek2024IDWEEK_542;
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy. (Pubmed Central) - Jun 28, 2024
These simulated results, when combined with the favorable observational data, support the use of commonly reported dalbavancin regimens for prolonged therapy durations. In addition, these pharmacokinetic/pharmacodynamic data support extending the dosing interval beyond the frequently reported weekly regimens, which should be investigated further with a clinical trial.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal, Real-world evidence, Real-world: Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience. (Pubmed Central) - Jun 17, 2024
Dalbavancin has proven to be an effective alternative as consolidation antibiotherapy for IE in elderly patients with comorbidity. Moreover, a very favorable safety profile with few associated adverse effects has been observed in this population.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal, Gram positive: Evaluation of two commercial broth microdilution systems for dalbavancin susceptibility testing of MRSA and other resistant Gram-positive cocci. (Pubmed Central) - Jun 10, 2024
This study, reporting the first evaluation of the two commercially available BMD assays for dalbavancin susceptibility testing, revealed an overall good correlation with reference BMD, although with some underestimation tendency of MIC values by both commercial systems. Further studies involving a higher number of resistant isolates will be necessary to better evaluate this issue.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Genome-wide CRISPRi screens for high-throughput fitness quantification and identification of determinants for dalbavancin susceptibility in Staphylococcus aureus. (Pubmed Central) - Jun 5, 2024
CRISPRi-seq offers a means to uncover untapped antibiotic targets, including those that conventional screens would disregard due to their essentiality. This paves the way for the discovery of new ways to fight infections.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature. (Pubmed Central) - May 16, 2024
This paves the way for the discovery of new ways to fight infections. Dalbavancin plasma concentrations were above 4
- | Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open: Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis (clinicaltrials.gov) - May 12, 2024
P4, N=100, Recruiting, Sponsor: University of Colorado, Denver
Dalbavancin plasma concentrations were above 4 Not yet recruiting --> Recruiting
- || Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review. (Pubmed Central) - May 11, 2024
Not yet recruiting --> Recruiting No abstract available
- | Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial completion date, Trial termination: Evaluation of Intravenous Dalbavancin for Peritonitis (clinicaltrials.gov) - May 9, 2024
P=N/A, N=2, Terminated, Sponsor: University of Colorado, Denver
No abstract available N=10 --> 2 | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated; Slow recruitment
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs. (Pubmed Central) - May 8, 2024
Where data is available, it was safe and effective. Dalbavancin appears a potentially valuable tool in improving outcomes for PWID.